| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RAX; PACT; DYT16; HSD14;;PRKRA |
| WB Predicted band size | 34 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PRKRA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于 **PRKRA抗体** 的参考文献示例(内容基于公开研究整理，部分为示例性描述)：
---
1. **文献名称**: *"PACT/PRKRA regulates cell proliferation and apoptosis via the mTOR pathway in glioblastoma"*
**作者**: Lee S, et al.
**摘要**: 本研究通过Western blot和免疫组化分析PRKRA(PACT)在胶质母细胞瘤中的表达，发现PRKRA抗体检测到其在肿瘤组织中显著上调。实验表明PRKRA通过mTOR信号通路调控细胞增殖和凋亡，为潜在治疗靶点提供依据。
2. **文献名称**: *"Functional characterization of PRKRA mutations in DYT16 dystonia using specific antibodies"*
**作者**: Patel N, et al.
**摘要**: 研究利用PRKRA特异性抗体分析DYT16型肌张力障碍患者的突变蛋白表达，发现突变导致PRKRA与PKR(蛋白激酶R)相互作用异常，影响内质网应激反应，提示其在神经退行性疾病中的病理机制。
3. **文献名称**: *"Antiviral role of PACT/PRKRA in RNA virus infection revealed by antibody-mediated knockdown"*
**作者**: Kim Y, et al.
**摘要**: 通过抗体介导的PRKRA蛋白敲低实验，证实其在RNA病毒(如流感病毒)感染中激活PKR并增强干扰素应答，强调了PRKRA抗体在抗病毒天然免疫研究中的工具价值。
4. **文献名称**: *"PRKRA expression profiling in breast cancer subtypes using immunohistochemistry"*
**作者**: Garcia-Rojas M, et al.
**摘要**: 利用PRKRA抗体对乳腺癌组织进行免疫组化分析，发现其在三阴性乳腺癌中高表达，且与患者预后不良相关，提示其作为生物标志物的潜在应用。
---
**注**：以上文献为示例性描述，实际引用时请以真实发表的论文为准，建议通过PubMed或Google Scholar检索关键词“PRKRA antibody”或“PACT protein”获取最新研究。
The PRKRA (Protein Kinase, Interferon-Inducible Double-Stranded RNA-Dependent Activator) gene encodes PACT, a critical regulatory protein involved in cellular stress responses and innate immunity. PRKRA/PACT interacts with the double-stranded RNA-dependent protein kinase (PKR), activating it under stress conditions to phosphorylate eIF2α, thereby modulating translation and promoting apoptosis. This pathway is vital in antiviral defense, tumor suppression, and neuronal signaling. Mutations in PRKRA are linked to dystonia 16 (DYT16), a movement disorder, and its dysregulation is implicated in cancer progression and neurodegenerative diseases.
PRKRA antibodies are essential tools for studying the protein's expression, localization, and function. They enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding research into PKR/PACT signaling dynamics. These antibodies are particularly valuable in exploring PRKRA's role in stress granule formation, viral response mechanisms, and disease pathogenesis. Commercially available PRKRA antibodies vary in specificity, with validation often performed using knockout cell lines or tissues. Challenges include distinguishing between phosphorylated and unmodified forms, as post-translational modifications regulate PACT's activity. Reliable PRKRA antibodies support both basic research and clinical investigations, offering insights into therapeutic targets for conditions linked to PKR/PACT pathway dysfunction.
×
